# Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection

> **NCT05152849** · PHASE2 · COMPLETED · sponsor: **Axcella Health, Inc** · enrollment: 41 (actual)

## Conditions studied

- Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

## Interventions

- **DRUG:** AXA1125
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05152849
- **Lead sponsor:** Axcella Health, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-15
- **Primary completion:** 2022-06-21
- **Final completion:** 2022-06-29
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2022-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05152849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05152849, "Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05152849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*